


Listing of the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

31. (Currently Amended) A compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof wherein:

Ar represents: pyridyl which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: (a) Cl, (b) Br, (c) F, (d) OH, (e) NO₂, (f) CF₃, (g) C₁₋₄ alkyl, (h) SCH₃, (i) NHCOCH₃, (j) N(R⁶)(R⁸) wherein R⁶ and R⁸ are the same or different and each represents H or C₁₋₄ alkyl, (k) OR¹⁰ wherein R¹⁰ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbonyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃, and (l) -OCOR¹¹ wherein R¹¹ represents a saturated or unsaturated C₁₋₆ straight or branched hydrocarbonyl group or a phenyl group;

R represents OH, OR¹⁰ or OCOR¹¹ wherein R¹⁰ and R¹¹ are as defined above; and R¹ represents H or a C₁₋₆ straight or branched hydrocarbonyl group which may be unsubstituted or substituted with from 1 to 3 substituents selected from Cl, Br, F, OMe, NO₂ and CF₃;

with the proviso that when R¹ is CH₃ and R is OH, then Ar cannot be 3-pyridyl or 4-pyridyl; and

when R¹ is CH₃ and Ar is 3-pyridyl, then R cannot be OCH₂CH=CH₂ or OCH₂C(CH₃)=CH₂.

Claims 32-35 (Canceled)

36. (Currently Amended) The compound of claim 31, wherein the substituents on the Ar group are selected from the group consisting of: NHCOCH_3 , $\text{N}(\text{R}^8)(\text{R}^8)$, $\text{N}(\text{R}^6)(\text{R}^8)$, OR^{10} , and $-\text{OCOR}^{11}$.

37. (Previously Added) The compound of claim 31, wherein Ar is substituted with one or more OR^{10} groups and R^{10} is a saturated or unsaturated C_{1-6} straight or branched hydrocarbonyl group.

38. (Previously Added) The compound of claim 37, wherein R^{10} is methyl.

39. (Canceled)

40. (Currently Amended) The compound of claim 31, wherein ~~R~~ R^{10} is an unsaturated C_{1-6} straight or branched hydrocarbonyl group.

41. (Previously Added) The compound of claim 40, wherein R is $\text{OCH}=\text{C}(\text{CH}_3)_2$, $\text{OCH}_2\text{CMe}=\text{CH}_2$, $\text{OCH}_2\text{CH}=\text{CH}_2$, or $\text{OCH}_2\text{C}\equiv\text{CH}$.

42. (Previously Added) The compound of claim 31, wherein Ar is selected from 3-pyridyl, and 4-pyridyl; and R is selected from $\text{OCH}=\text{C}(\text{CH}_3)_2$, $\text{OCH}_2\text{CMe}=\text{CH}_2$, $\text{OCH}_2\text{CH}=\text{CH}_2$ or $\text{OCH}_2\text{C}\equiv\text{CH}$.

43. (Currently Amended) The compound of claim 31, wherein Ar is selected from 3-pyridyl and 4-pyridyl and R is selected from OH , ~~or OCH_2R^+ , wherein R^+ is selected from $\text{CH}=\text{CMe}_2$, $\text{CMe}=\text{CH}_2$, $\text{CH}=\text{CH}_2$ and $\text{C}\equiv\text{CH}$~~ $\text{OCH}=\text{C}(\text{CH}_3)_2$, $\text{OCH}_2\text{CH}=\text{C}(\text{CH}_3)_2$, $\text{OCH}_2\text{C}(\text{CH}_3)=\text{CH}_2$, $\text{OCH}_2\text{CH}=\text{CH}_2$, and $\text{OCH}_2\text{C}\equiv\text{CH}$.

44. (Previously Added) The compound of claim 31, wherein R^6 and R^8 are the same or different and each is independently H or C_{1-4} alkyl.

45. (Previously Added) The compound of claim 31, wherein R¹⁰ and R¹¹ are each independently a saturated or unsaturated C₁₋₆ straight chain or branched hydrocarbyl group.

46. (Previously Added) The compound of claim 45, wherein R¹⁰ and R¹¹ are selected from methyl, ethyl, n-propyl, and isopropyl.

47. (Currently Amended) The compound of claim 31, selected from the group consisting of:

~~1-[4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one;~~

1-[4-methyl-7-(2-methylprop-1-enyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one;

1-[4-methyl-7-(2-methylallyloxy)coumarin-8-yl]-3-(pyridine-3-yl)propen-1-one;

1-[4-methyl-7-(allyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one; and

1-[4-methyl-7-(prop-2-ynyloxy)coumarin-8-yl]-3-(pyridin-3-yl)propen-1-one.

Claims 48 - 54 (Canceled)

55. (Previously Added) A pharmaceutical composition comprising a compound of claim 31 and a pharmaceutically acceptable excipient.

Claims 56 - 57 (Canceled)